Epicardial angiogenesis patch - Theregen Corporation

Drug Profile

Epicardial angiogenesis patch - Theregen Corporation

Alternative Names: Anginera

Latest Information Update: 08 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theregen
  • Class Fibroblast cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Heart failure; Ischaemic heart disorders

Most Recent Events

  • 07 Dec 2007 Theregen completes enrolment in its phase I trial for Ischaemic heart disorders in USA
  • 25 Jul 2007 Phase-I clinical trials in Heart failure in USA (Perilesional)
  • 10 May 2006 Phase-I clinical trials in Ischaemic heart disorders in USA (Perilesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top